This is a bit of an aside, but I hesitate to be too shocked by differences in funding:DALY ratios. After all, what you really want to know is change in DALYs at a given level of funding. It seems pretty plausible that some diseases are 10x (or even 100x) as cost-effective to ameliorate as others.
That said, funding:DALY seems like a fine heuristic for searching for misallocated resources. And to be clear, I expect it’s not actually a difference in cost-effectiveness that’s driving the different spending, but I’d want to check before updating too much.
This is a bit of an aside, but I hesitate to be too shocked by differences in funding:DALY ratios. After all, what you really want to know is change in DALYs at a given level of funding. It seems pretty plausible that some diseases are 10x (or even 100x) as cost-effective to ameliorate as others.
That said, funding:DALY seems like a fine heuristic for searching for misallocated resources. And to be clear, I expect it’s not actually a difference in cost-effectiveness that’s driving the different spending, but I’d want to check before updating too much.